Ying Kou Shi

Researchers are investigating the effectiveness and safety of oral minocycline compared to placebo in patients who have experienced an acute spontaneous intracerebral hemorrhage within 48 hours of symptom onset. This phase III clinical trial is designed as a prospective, multicenter, randomized, double-blind, placebo-controlled study aiming to improve recovery outcomes in this patient population. An additional goal is to assess the impact of minocycline on markers of venous neuroinflammation at various times after the hemorrhage. A total of 1192 participants will be randomly assigned in equal numbers to receive either minocycline capsules containing 50 mg of minocycline hydrochloride or matching placebo capsules for five days. All participants will also receive standard medical care based on current guidelines. The study includes three phases: screening and baseline, treatment, and follow-up. Participants will be evaluated at several time points including screening/baseline, 72 ±12 hours, 7 ±1 days, 90 ±7 days, and 180 ±7 days after randomization, as well as during any relevant events. Researchers will measure the primary outcome of disability and functional status using the modified Rankin Scale score (mRS) at 90 days post-randomization, aiming for scores between 0 and 3. Throughout the study, assessments and interviews will monitor safety, efficacy, and treatment adherence.

Chronic kidney disease (CKD) is a serious health concern, with primary glomerulonephritis being a leading cause in 50% to 60% of cases. This research aims to evaluate the safety and effectiveness of Huaiqihuang Granule, a traditional Chinese herbal medicine, in treating patients with stage 3 CKD caused by primary glomerulonephritis. The study is a phase 4, multicenter, randomized, double-blind, positive-drug controlled trial conducted across about 40 top hospitals in China. Participants will be randomly assigned to receive either Huaiqihuang Granules or Valsartan capsules. The Huaiqihuang group will take 2 bags of granules three times daily, while the Valsartan group will take 80 mg capsules once daily, with each group receiving a simulant of the other drug to maintain blinding. All medications are taken orally over a treatment period of 48 weeks, with follow-up visits scheduled at weeks 0, 8, 16, 24, 32, 40, and 48. During the study, participants will be monitored through regular visits to assess kidney function and overall health. The main outcome measured is the rate of change in estimated glomerular filtration rate (eGFR) from the start to week 48. The study also tracks safety and adherence, ensuring participants meet the eligibility requirements and receive ongoing evaluation throughout the nearly one-year participation period.

Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants (DOACs) early versus later in patients who have acute ischemic stroke related to atrial fibrillation and who have undergone emergency endovascular therapy (EVT). This multicenter, prospective, open-label randomized controlled trial focuses on different timings to begin DOAC therapy to improve outcomes and reduce risks after stroke. Patients will be randomly assigned to one of two groups: the early anticoagulation group, which starts DOACs within four days of symptom onset, and the delayed anticoagulation group, which begins DOACs between 5 and 14 days after symptom onset. The study observes these treatment timings after emergency EVT for stroke, assessing their effects on patient safety and stroke recurrence. Participants will be monitored closely for 90 days after treatment to assess outcomes including recurrent ischemic stroke, symptomatic intracranial hemorrhage, and death from any cause. Evaluations include clinical assessments and imaging such as CT or MRI to detect hemorrhagic changes. Researchers will also review medical history, stroke severity, and treatment adherence. The study involves follow-up visits and data collection to ensure thorough safety and efficacy analysis over the three-month period.

Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants (DOACs) early versus delaying their start in patients who have had an acute ischemic stroke related to atrial fibrillation and developed bleeding in the brain after emergency endovascular treatment. This is a multicenter, open-label, randomized controlled trial focusing on different timings for beginning DOAC therapy to improve patient outcomes after stroke. Participants are assigned to one of two groups: early anticoagulation, where DOACs are started within 4 weeks after stroke symptoms begin, or delayed anticoagulation, where DOACs are started between 4 to 8 weeks after symptom onset. The study compares these two approaches to understand which timing is safer and more effective in managing stroke patients who experienced hemorrhagic transformation after treatment. During the study, patients will be monitored for a composite outcome including recurrent ischemic stroke, symptomatic brain bleeding, and death from any cause within 90 days. Researchers will conduct assessments and follow patients closely during this period to evaluate the effects of the timing of anticoagulant initiation. Participants will be followed up for 90 days to track these outcomes and assess safety and efficacy.